Status:
COMPLETED
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Progressive Supranuclear Palsy
Corticobasal Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge. These rare severe neurodegenerative extrapyramidal movement disord...
Eligibility Criteria
Inclusion
- PSP or CBD patients for whom a treatment with subcutaneaous apomorphine is indicated
Exclusion
- Pregnant or breastfeeding women
- Patient under a legal protection procedure
- Patient denying to participated to the study
- Lack of affiliation to a social security system
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04786158
Start Date
December 1 2018
End Date
July 1 2020
Last Update
March 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Fondation Adolphe de Rothschild
Paris, Île-de-France Region, France, 75019